What is Löfgren's syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Löfgren's Syndrome?

Löfgren's syndrome is an acute, self-limiting variant of sarcoidosis defined by the classic triad of bilateral hilar lymphadenopathy with erythema nodosum and/or periarticular arthritis. 1

Clinical Definition and Diagnostic Criteria

According to the 2020 American Thoracic Society guidelines, Löfgren's syndrome represents a "highly probable" clinical presentation of sarcoidosis that can be diagnosed without requiring tissue biopsy 1. The syndrome is characterized by:

  • Bilateral hilar lymphadenopathy (visible on chest X-ray, CT, or PET imaging)
  • Erythema nodosum (tender, erythematous subcutaneous nodules, typically on the lower extremities)
  • Periarticular arthritis or arthralgia (most commonly affecting the ankles symmetrically)

The simultaneous presence of these three elements is sufficiently specific that histopathologic confirmation is not required for diagnosis 2. This distinguishes Löfgren's syndrome from other forms of sarcoidosis, which typically require biopsy showing non-caseating granulomas.

Clinical Presentation and Key Features

Patients typically present as young to middle-aged adults with:

  • Acute onset of bilateral ankle and foot pain, swelling, and erythema
  • Fever (common accompanying symptom)
  • Painful subcutaneous nodules on the lower extremities consistent with erythema nodosum 3, 4, 5
  • Polyarthritis that may extend beyond the ankles to involve knees and wrists 5

Important Diagnostic Pitfall

Löfgren's syndrome is frequently misdiagnosed as cellulitis when patients present with bilateral lower extremity erythema and swelling 4. The key distinguishing feature is lack of response to antibiotics—if a patient with presumed bilateral cellulitis fails to improve on broad-spectrum antibiotics, Löfgren's syndrome should be strongly considered, particularly if systemic symptoms are present.

Diagnostic Workup

When Löfgren's syndrome is suspected:

  1. Chest imaging (X-ray or CT) to confirm bilateral hilar lymphadenopathy
  2. Laboratory testing may show:
    • Neutrophilic leukocytosis
    • Elevated inflammatory markers
    • Serum ACE levels (may be normal or elevated—normal ACE does not exclude the diagnosis) 4
  3. Exclusion of alternative diagnoses, particularly:
    • Tuberculosis (critical in endemic areas) 5
    • Lymphoma
    • Infectious causes
    • Autoimmune conditions

If diagnosis remains uncertain, bronchoscopy with bronchoalveolar lavage may reveal elevated CD4:CD8 ratio (>3.5), and endobronchial ultrasound-guided biopsy can confirm non-caseating granulomas 4.

Prognosis and Clinical Course

Löfgren's syndrome generally carries an excellent prognosis with spontaneous resolution or minimal treatment required 2. This acute variant of sarcoidosis is self-limiting in most cases, distinguishing it from chronic sarcoidosis which may require prolonged immunosuppression.

Treatment Approach

First-line therapy is NSAIDs alone, which typically produce rapid clinical improvement 4, 2.

Low-dose glucocorticoids (prednisolone) are reserved for cases with more aggressive disease or inadequate response to NSAIDs 5, 2.

Important Treatment Considerations

In Asian populations, particularly Chinese patients, treatment may require longer duration and more careful titration of glucocorticoids compared to Western populations 3. Asian patients with Löfgren's syndrome are more likely to experience delayed diagnosis and may need lengthier glucocorticoid therapy, possibly due to genetic differences in disease expression and immune response.

Critical Caveat with TNF-α Inhibitors

When Löfgren's syndrome coexists with other rheumatic diseases, TNF-α inhibitors (such as adalimumab) should be used with extreme caution, as they may precipitate disease relapse 3. This is particularly relevant in patients with concurrent ankylosing spondylitis or other conditions requiring biologic therapy.

Population-Specific Considerations

Löfgren's syndrome has low incidence in Asian populations, contributing to limited clinical awareness and diagnostic challenges in these regions 3. Predominantly affects women in their second and third decades of life in Western populations 2, though the demographic pattern may vary by ethnicity.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.